The Effect of Peginterferon Alpha-2a Vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study

Overview

Journal Hepat Mon

Publisher Brieflands

Specialty Gastroenterology

Date 2013 Aug 8

PMID 23922556

Citations 14

Authors

Maissa El Raziky

Waleed Fouad Fathalah

Wafaa Ahmed El-Akel

Ahmed Salama

Gamal Esmat

Mahassen Mabrouk

Rabab Mamoun Salama

Hany Mahmoud Khatab

Affiliations

Soon will be listed here.

Abstract

Background: Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naive HCV-infected patients have shown conflicting results.

Objectives: Assessing the effects of Peginterferon alpha-2a versus Peginterferon alpha-2b on the sustained virological response in naive chronic HCV genotype-4 Egyptian patients.

Patients And Methods: This retrospective study cohort consists of 3718 chronic HCV patients admitted to a large, Egyptian medical center. 1985 patients had been treated with PEG-IFN alfa-2a plus RBV and 1733 patients with PEG-IFN alfa-2b plus RBV between years 2007-2011. Efficacy outcomes were sustained virologic response (SVR) and treatment discontinuation rates due to serious adverse effects.

Results: The ETR & SVR in patients treated with PEGIFN alfa-2a was 64.1% and 59.6% as compared to treatment with PEGIFN alfa-2b where these parameters were 58.2% and 53.9% respectively (P < 0.05). Treatment discontinuation rates, were similar in the two types of PEGIFN [0.66 (0.37-1.16); P = 0.15]. Significant dose reduction was evident with peginterferon alfa-2b (35.3%) than peginterferon alpha-2a (27.3 %) (P < 0.01). Patients with lower base line AFP and ALT were most likely to achieve SVR using INF alpha 2-a.

Conclusions: Peginterferon alpha-2a has a higher efficacy regarding ETR and SVR as compared to Peginterferon alfa-2b in treatment of naive chronic HCV genotype-4 patients.

Citing Articles

The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.

Naguib G, Michael T, Elshazly Y, Wahdan M, Mostafa A, Ahmed O Virusdisease. 2021; 32(3):582-588.

PMID: 34631983 PMC: 8473466. DOI: 10.1007/s13337-021-00712-4.

ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides.

Timmons P, Hewage C Brief Bioinform. 2021; 22(6).

PMID: 34297817 PMC: 8575049. DOI: 10.1093/bib/bbab258.

Antiviral peptides as promising therapeutic drugs.

Vilas Boas L, Campos M, Berlanda R, de Carvalho Neves N, Franco O Cell Mol Life Sci. 2019; 76(18):3525-3542.

PMID: 31101936 PMC: 7079787. DOI: 10.1007/s00018-019-03138-w.

Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.

Omran D, Alboraie M, Zayed R, Wifi M, Naguib M, Eltabbakh M World J Gastroenterol. 2018; 24(38):4330-4340.

PMID: 30344418 PMC: 6189850. DOI: 10.3748/wjg.v24.i38.4330.

Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt's hepatocellular cancer epidemic: simulation of alternatives.

Ma W, Soliman A, Anwar W, Hablas A, El Din T, Ramadan M BMJ Glob Health. 2018; 3(2):e000572.

PMID: 29707244 PMC: 5914708. DOI: 10.1136/bmjgh-2017-000572.

References

Bekkering F, Neumann A, Brouwer J, Schalm S . Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol. 2002; 1:14. PMC: 64636. DOI: 10.1186/1471-230x-1-14. View

Shepherd J, BRODIN H, Cave C, Waugh N, Price A, Gabbay J . Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2004; 8(39):iii-iv, 1-125. DOI: 10.3310/hta8390. View

Strader D, Wright T, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. DOI: 10.1002/hep.20119. View

Bedossa P, Poynard T . An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2):289-93. DOI: 10.1002/hep.510240201. View

Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C . Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010; 51(4):1176-84. DOI: 10.1002/hep.23504. View

Schaefer M, Heinz A, Backmund M . Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction. 2004; 99(9):1167-75. DOI: 10.1111/j.1360-0443.2004.00821.x. View

Darwish M, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy M . Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg. 2001; 64(3-4):147-53. DOI: 10.4269/ajtmh.2001.64.147. View

Ascione A, De Luca M, Tartaglione M, Lampasi F, Di Costanzo G, Lanza A . Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2009; 138(1):116-22. DOI: 10.1053/j.gastro.2009.10.005. View

Sullivan S, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N . Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics. 2004; 22(4):257-65. DOI: 10.2165/00019053-200422040-00004. View

10.

Alavian S, Behnava B, Tabatabaei S . The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2012; 10(2):121-31. PMC: 3270355. View

11.

Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales Jr F . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82. DOI: 10.1056/NEJMoa020047. View

12.

Rumi M, Aghemo A, Prati G, DAmbrosio R, Donato M, Soffredini R . Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2009; 138(1):108-15. DOI: 10.1053/j.gastro.2009.08.071. View

13.

McHutchison J, Sulkowski M . Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2008; 15(7):475-81. DOI: 10.1111/j.1365-2893.2008.00973.x. View

14.

. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 2000; 6(1):35-47. View

15.

Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B . Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat. 2010; 17(7):459-68. DOI: 10.1111/j.1365-2893.2009.01255.x. View

16.

McHutchison J, Lawitz E, Shiffman M, Muir A, Galler G, McCone J . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6):580-93. DOI: 10.1056/NEJMoa0808010. View

17.

Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L . Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther. 2004; 9(4):491-7. View

18.

Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A . Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2008; 49(1):22-31. DOI: 10.1002/hep.22598. View

19.

Ray S, Arthur R, Carella A, Bukh J, Thomas D . Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis. 2000; 182(3):698-707. DOI: 10.1086/315786. View